Moderna (NASDAQ:MRNA) Research Coverage Started at Wolfe Research

Wolfe Research assumed coverage on shares of Moderna (NASDAQ:MRNA) in a research report sent to investors on Friday morning, Marketbeat reports. The brokerage issued an underperform rating and a $40.00 price objective on the stock.

Several other equities research analysts have also weighed in on MRNA. Jefferies Financial Group reduced their price objective on Moderna from $65.00 to $55.00 and set a “hold” rating for the company in a research note on Tuesday, October 15th. Royal Bank of Canada reissued a “sector perform” rating and issued a $75.00 price target on shares of Moderna in a research note on Thursday, September 19th. TD Cowen cut their price objective on Moderna from $70.00 to $60.00 and set a “hold” rating on the stock in a report on Friday, September 13th. Bank of America decreased their target price on shares of Moderna from $130.00 to $110.00 and set a “neutral” rating for the company in a report on Friday, September 13th. Finally, JPMorgan Chase & Co. cut their price target on shares of Moderna from $70.00 to $59.00 and set an “underweight” rating on the stock in a report on Monday, November 4th. Three analysts have rated the stock with a sell rating, fourteen have issued a hold rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $90.22.

Moderna Price Performance

Shares of Moderna stock opened at $36.85 on Friday. Moderna has a 52 week low of $35.80 and a 52 week high of $170.47. The company has a current ratio of 4.39, a quick ratio of 4.20 and a debt-to-equity ratio of 0.05. The company’s 50-day moving average price is $58.56 and its two-hundred day moving average price is $96.78. The stock has a market cap of $14.18 billion, a PE ratio of -6.33 and a beta of 1.69.

Moderna (NASDAQ:MRNA) last released its earnings results on Thursday, November 7th. The company reported $0.03 EPS for the quarter, beating the consensus estimate of ($1.89) by $1.92. The business had revenue of $1.90 billion during the quarter, compared to analyst estimates of $1.25 billion. Moderna had a negative net margin of 43.77% and a negative return on equity of 17.68%. The business’s quarterly revenue was up 3.8% on a year-over-year basis. During the same period in the prior year, the business earned ($1.39) earnings per share. As a group, sell-side analysts anticipate that Moderna will post -9.43 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, CFO James M. Mock sold 715 shares of the business’s stock in a transaction that occurred on Monday, October 7th. The stock was sold at an average price of $60.12, for a total value of $42,985.80. Following the completion of the sale, the chief financial officer now owns 9,505 shares of the company’s stock, valued at approximately $571,440.60. The trade was a 7.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Insiders have sold a total of 2,930 shares of company stock valued at $217,170 in the last three months. Insiders own 15.70% of the company’s stock.

Institutional Trading of Moderna

Several large investors have recently added to or reduced their stakes in the business. Empowered Funds LLC boosted its holdings in Moderna by 26.8% in the first quarter. Empowered Funds LLC now owns 4,276 shares of the company’s stock worth $456,000 after purchasing an additional 904 shares in the last quarter. Sei Investments Co. lifted its position in shares of Moderna by 16.4% in the first quarter. Sei Investments Co. now owns 84,910 shares of the company’s stock worth $9,048,000 after buying an additional 11,977 shares during the last quarter. US Bancorp DE boosted its stake in shares of Moderna by 19.5% during the 1st quarter. US Bancorp DE now owns 23,107 shares of the company’s stock worth $2,462,000 after acquiring an additional 3,771 shares in the last quarter. Avantax Advisory Services Inc. increased its holdings in shares of Moderna by 53.3% during the 1st quarter. Avantax Advisory Services Inc. now owns 5,035 shares of the company’s stock valued at $537,000 after acquiring an additional 1,750 shares during the last quarter. Finally, Bleakley Financial Group LLC lifted its holdings in Moderna by 10.8% in the 1st quarter. Bleakley Financial Group LLC now owns 3,711 shares of the company’s stock worth $395,000 after purchasing an additional 362 shares during the last quarter. 75.33% of the stock is owned by institutional investors.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.